Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated pressures in the pulmonary arteries. Understanding its pathophysiology, diagnosis, and management is crucial for healthcare professionals.
PH originates from diverse etiologies leading to remodeling of the pulmonary vasculature, resulting in increased pulmonary vascular resistance and pulmonary arterial pressure. This ultimately causes right ventricular hypertrophy and heart failure.
Diagnosis of PH can be challenging due to its nonspecific symptoms. Initial diagnosis involves echocardiography, followed by right heart catheterization for confirmation. Additionally, various other tests like pulmonary function tests, chest radiography, and computed tomography can aid in identifying the underlying causes.
PH is classified into five groups based on etiology: Pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung diseases and/or hypoxia, Chronic thromboembolic PH (CTEPH), and PH with unclear multifactorial mechanisms. Each group requires a different treatment approach.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include oxygen therapy, diuretics, and anticoagulation. Specific therapies for PAH include endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogues. In cases of CTEPH, pulmonary endarterectomy or balloon pulmonary angioplasty may be considered.
The prognosis of PH is generally poor, with survival rates varying greatly depending on the underlying cause. However, early diagnosis and appropriate management can significantly improve patient outcomes.
As healthcare professionals, it is essential to understand the complexities of PH to ensure accurate diagnosis and effective treatment. Continued research and advancements in targeted therapies hold promise for improved prognosis and quality of life for patients with PH.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation